vs
PUMA BIOTECHNOLOGY, INC.（PBYI）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是REGIS CORP的1.3倍（$75.5M vs $57.1M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 22.3%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $891.0K），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 7.8%）
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
PBYI vs RGS — 直观对比
营收规模更大
PBYI
是对方的1.3倍
$57.1M
营收增速更快
PBYI
高出5.5%
22.3%
自由现金流更多
PBYI
多$13.5M
$891.0K
两年增速更快
PBYI
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $75.5M | $57.1M |
| 净利润 | — | $456.0K |
| 毛利率 | 69.3% | — |
| 营业利润率 | 22.7% | 10.8% |
| 净利率 | — | 0.8% |
| 营收同比 | 27.7% | 22.3% |
| 净利润同比 | — | -94.0% |
| 每股收益（稀释后） | $0.26 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PBYIRGS
| Q4 25 | $75.5M | $57.1M | ||
| Q3 25 | $54.5M | $59.0M | ||
| Q2 25 | $52.4M | $60.4M | ||
| Q1 25 | $46.0M | $57.0M | ||
| Q4 24 | $59.1M | $46.7M | ||
| Q3 24 | $80.5M | $46.1M | ||
| Q2 24 | $47.1M | $49.4M | ||
| Q1 24 | $43.8M | $49.2M |
净利润PBYIRGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | $8.8M | $1.4M | ||
| Q2 25 | $5.9M | $116.5M | ||
| Q1 25 | $3.0M | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $20.3M | $-853.0K | ||
| Q2 24 | $-4.5M | $91.2M | ||
| Q1 24 | $-4.8M | $-2.3M |
毛利率PBYIRGS
| Q4 25 | 69.3% | — | ||
| Q3 25 | 77.7% | — | ||
| Q2 25 | 76.5% | — | ||
| Q1 25 | 77.1% | — | ||
| Q4 24 | 76.4% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 77.4% | — | ||
| Q1 24 | 75.5% | — |
营业利润率PBYIRGS
| Q4 25 | 22.7% | 10.8% | ||
| Q3 25 | 17.6% | 10.0% | ||
| Q2 25 | 12.7% | 12.1% | ||
| Q1 25 | 8.7% | 8.8% | ||
| Q4 24 | 22.6% | 11.8% | ||
| Q3 24 | 27.4% | 4.6% | ||
| Q2 24 | -4.6% | — | ||
| Q1 24 | -5.3% | 8.3% |
净利率PBYIRGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | 16.2% | 2.3% | ||
| Q2 25 | 11.2% | 192.9% | ||
| Q1 25 | 6.5% | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | 25.2% | -1.9% | ||
| Q2 24 | -9.6% | 184.7% | ||
| Q1 24 | -11.0% | -4.7% |
每股收益（稀释后）PBYIRGS
| Q4 25 | $0.26 | $0.16 | ||
| Q3 25 | $0.17 | $0.49 | ||
| Q2 25 | $0.12 | $43.67 | ||
| Q1 25 | $0.06 | $0.08 | ||
| Q4 24 | $0.40 | $2.71 | ||
| Q3 24 | $0.41 | $-0.36 | ||
| Q2 24 | $-0.09 | $38.40 | ||
| Q1 24 | $-0.10 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $97.5M | $18.4M |
| 总债务越低越好 | $22.7M | $113.3M |
| 股东权益账面价值 | $130.3M | $188.7M |
| 总资产 | $216.3M | $588.3M |
| 负债/权益比越低杠杆越低 | 0.17× | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资PBYIRGS
| Q4 25 | $97.5M | $18.4M | ||
| Q3 25 | $94.4M | $16.6M | ||
| Q2 25 | $96.0M | $17.0M | ||
| Q1 25 | $93.2M | $13.3M | ||
| Q4 24 | $101.0M | $10.2M | ||
| Q3 24 | $96.7M | $6.3M | ||
| Q2 24 | $96.8M | $10.1M | ||
| Q1 24 | $107.2M | $5.9M |
总债务PBYIRGS
| Q4 25 | $22.7M | $113.3M | ||
| Q3 25 | $34.0M | $111.3M | ||
| Q2 25 | $45.3M | $110.8M | ||
| Q1 25 | $56.7M | $112.0M | ||
| Q4 24 | $68.0M | $111.5M | ||
| Q3 24 | $79.3M | $95.2M | ||
| Q2 24 | $90.7M | $99.5M | ||
| Q1 24 | $102.0M | $179.7M |
股东权益PBYIRGS
| Q4 25 | $130.3M | $188.7M | ||
| Q3 25 | $115.3M | $187.6M | ||
| Q2 25 | $104.7M | $185.6M | ||
| Q1 25 | $97.1M | $68.6M | ||
| Q4 24 | $92.1M | $66.7M | ||
| Q3 24 | $71.1M | $56.4M | ||
| Q2 24 | $48.5M | $56.8M | ||
| Q1 24 | $51.0M | $-35.8M |
总资产PBYIRGS
| Q4 25 | $216.3M | $588.3M | ||
| Q3 25 | $202.9M | $592.1M | ||
| Q2 25 | $194.9M | $599.0M | ||
| Q1 25 | $196.2M | $511.2M | ||
| Q4 24 | $213.3M | $530.1M | ||
| Q3 24 | $220.7M | $508.9M | ||
| Q2 24 | $205.0M | $530.5M | ||
| Q1 24 | $214.1M | $543.7M |
负债/权益比PBYIRGS
| Q4 25 | 0.17× | 0.60× | ||
| Q3 25 | 0.30× | 0.59× | ||
| Q2 25 | 0.43× | 0.60× | ||
| Q1 25 | 0.58× | 1.63× | ||
| Q4 24 | 0.74× | 1.67× | ||
| Q3 24 | 1.12× | 1.69× | ||
| Q2 24 | 1.87× | 1.75× | ||
| Q1 24 | 2.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $14.4M | $891.0K |
| 自由现金流率自由现金流/营收 | 19.1% | 1.6% |
| 资本支出强度资本支出/营收 | 0.0% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $41.7M | $14.9M |
8季度趋势，按日历期对齐
经营现金流PBYIRGS
| Q4 25 | $14.4M | $1.7M | ||
| Q3 25 | $9.7M | $2.3M | ||
| Q2 25 | $14.1M | $6.8M | ||
| Q1 25 | $3.6M | $6.2M | ||
| Q4 24 | $15.6M | $2.1M | ||
| Q3 24 | $11.0M | $-1.3M | ||
| Q2 24 | $1.0M | $5.1M | ||
| Q1 24 | $11.2M | $-277.0K |
自由现金流PBYIRGS
| Q4 25 | $14.4M | $891.0K | ||
| Q3 25 | $9.7M | $1.9M | ||
| Q2 25 | $14.1M | $6.2M | ||
| Q1 25 | $3.6M | $5.9M | ||
| Q4 24 | $15.6M | $1.7M | ||
| Q3 24 | $11.0M | $-1.4M | ||
| Q2 24 | $1.0M | $5.1M | ||
| Q1 24 | — | $-326.0K |
自由现金流率PBYIRGS
| Q4 25 | 19.1% | 1.6% | ||
| Q3 25 | 17.7% | 3.2% | ||
| Q2 25 | 26.8% | 10.3% | ||
| Q1 25 | 7.7% | 10.3% | ||
| Q4 24 | 26.4% | 3.6% | ||
| Q3 24 | 13.7% | -3.0% | ||
| Q2 24 | 2.1% | 10.3% | ||
| Q1 24 | — | -0.7% |
资本支出强度PBYIRGS
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.1% | 0.6% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.0% | ||
| Q1 24 | 0.0% | 0.1% |
现金转化率PBYIRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | 1.10× | 1.68× | ||
| Q2 25 | 2.41× | 0.06× | ||
| Q1 25 | 1.21× | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PBYI
暂无分部数据
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
